首页|美罗培南负荷剂量两步输注法治疗重症感染疗效的回顾性分析

美罗培南负荷剂量两步输注法治疗重症感染疗效的回顾性分析

扫码查看
目的 探讨美罗培南负荷剂量两步输注法治疗重症感染患者与传统间歇静滴法比较,是否能获得更高的临床疗效及细菌学疗效。方法 采用回顾性研究方法,收集某院 2022 年使用美罗培南治疗重症感染患者病例,对比分析评价两种给药方案治疗的主要临床有效性参数(白细胞计数、中性粒细胞比率、降钙素原水平)、微生物学有效性参数(细菌清除率)及药品不良反应发生情况。结果 两组患者的临床有效率、细菌清除率比较,差异无统计学意义(P>0。05)。治疗第 7 天及停药当天,两组中性粒细胞比率下降值比较,差异有统计学意义(P<0。05)。两组均未发生药品不良反应。结论 美罗培南负荷剂量两步输注法治疗重症感染的有效性及安全性可能与传统间歇静滴法一致,但部分指标的临床改善情况可能优于传统间歇静滴法。
Retrospective analysis of the efficacy of meropenem loading dose two-step infusion method in the treatment of severe infections
Objective Exploring whether the two-step infusion method of meropenem loading dose can achieve higher clinical and bacteriolog-ical efficacy in the treatment of severe infection patients compared to traditional intermittent intravenous drip method.Methods A retrospective study was conducted to collect cases of patients with severe infections treated with meropenem in a hospital in 2022.Comparative analysis and evaluation of the main clinical efficacy parameters(white blood cell count,neutrophil ratio,procalcitonin level),microbiological efficacy parameters(bacterial clearance rate),and incidence of adverse drug reactions between two dosing regimens.Results The differences in clinical efficiency and bacterial clearance rates between the two groups were not statistically significant(P>0.05).The difference in the value of the decrease in neutrophil ratio between the two groups on the 7th day of treatment and on the day of medication discontinuation was statistically significant(P<0.05).No adverse drug reactions occurred in either group.Conclusion The effectiveness and safety of the two-step infusion of meropenem load dose in the treatment of severe infections may be consistent with traditional intermittent intravenous infusion,but some indexes may have better clinical improvement than traditional intermittent intravenous drip method.

MeropenemLoading dose two-step infusion methodSevere infectionRetrospective study

李蓉、宋杲、白中平

展开 >

普洱市人民医院药学部,云南普洱 665000

美罗培南 负荷剂量两步输注法 重症感染 回顾性研究

云南省科技厅科技计划项目

202201AY070001-294

2024

中国处方药
南方医药经济研究所

中国处方药

影响因子:0.649
ISSN:1671-945X
年,卷(期):2024.22(6)